Acid-related diseases occupy a leading place in the structure of the incidence of the gastrointestinal tract. One of the important aspects of studying them now is to consider them in combination with coronary heart disease, hypertension, diabetes, asthma and other common diseases and conditions. Proton pump inhibitors are currently the basis for the treatment of acid-related diseases. Although all PPIs are very effective, the antisecretory effects of various drugs of this class may differ in different patients, especially in the presence of comorbidities and comorbidities. The pharmacokinetics and metabolism of rabeprazole are significantly different from those of other IPPs. The clearance of rabeprazole is largely non-enzymatic and depends little on the functioning of the cytochrome P450 (CYP) 2C19 system, which determines the predictability of the effect of rabeprazole and its safety for patients taking several drugs at the same time. A distinctive effect of rabeprazole is the activation of rabeprazole in a wide pH range, the presence of a gastroprotective effect and anti-helicobacter activity.